Pembrolizumab-belzutifan tied to improved disease-free survival in renal cell carcinoma
For patients with clear-cell renal cell carcinoma, pembrolizumab-belzutifan yields significantly higher disease-free survival, according to a study published in the July 2 issue of the New England Journal of Medicine.